Sequent Scientific shares jumped nearly 9% on September 26, 2024, after the company announced a merger with Viyash Life Sciences.
The merger will create a platform with leadership in animal pharmaceuticals and integrated capabilities across the global pharmaceutical market, backed by strong operational and R&D capabilities, as per the stock exchange filing.
The board of directors of Sequent Scientific approved a composite scheme of amalgamation for the merger of Viyash Life Sciences and its group companies with Sequent Research Limited, a wholly-owned subsidiary of Sequent Scientific, under the Companies Act, 2013.
As of 10:21 am, shares of Sequent Scientific were trading 8.59% higher at ₹207.88 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
